Aug 2026· Materials Today Bio· Vol 40, pp. 103535· 0 citations· 33 references
Medicine
TL;DR
This study establishes a non-antibiotic nanozyme-based therapeutic strategy that is efficient, low in toxicity, and non-invasive for treating MDR bacterial infections and provides a solid theoretical basis and technical framework for the rational design of defect/interface dual-engineered nanoplatforms.
Abstract
Managing pneumonia caused by multidrug-resistant (MDR) bacteria presents significant clinical challenges. The near-infrared II (NIR-II) laser irradiance exhibits strong photothermal conversion capabilities, making it a promising candidate for photothermal and chemodynamic therapies as non-antibiotic strategies. However, traditional methods are often hindered by issues such as the uncontrollable production of reactive oxygen species and the low efficiency associated with NIR-II photothermal therapy. This underscores the necessity for precisely regulated and highly effective synergistic therapies. To address these limitations, we have innovatively developed a defect/interface dual-engineered nanozyme (PtPb@SbO3-x) and comprehensively characterized its atomic-scale structure and catalytic mechanisms using density functional theory calculations and synchrotron radiation techniques. In vitro experiments demonstrated that PtPb@SbO3-x could efficiently eliminate drug-resistant bacteria and disrupt biofilm structures under low-concentration hydrogen peroxide and NIR-II irradiation while exhibiting excellent biocompatibility. In pneumonia models, the nanozyme enabled rapid infection clearance and significantly reduced inflammatory responses via synergistic photothermal and chemodynamic therapy effects. Furthermore, integrated multi-omics analyses-including metabolomics, transcriptomics, and proteomics-systematically uncovered the molecular mechanisms driving its therapeutic efficacy. This study successfully establishes a non-antibiotic nanozyme-based therapeutic strategy that is efficient, low in toxicity, and non-invasive for treating MDR bacterial infections. It also provides a solid theoretical basis and technical framework for the rational design of defect/interface dual-engineered nanoplatforms.
The NCRPF nanotherapeutic system provides a powerful new paradigm with high translational potential for the complete eradication of breast cancer, and both in vitro and in vivo results confirm that this combined strategy achieves complete tumor eradication with favorable biosafety.
A gallium-porphyrin metal–organic framework that functions as an all-in-one theranostic platform by simultaneously delivering high-flux singlet oxygen and controlled Ga3+ release is reported, establishing a single-material theranostic paradigm that conjoins mechanistic diagnostics with potent antibacterial therapy.
Combination therapies involving chemotherapy and photothermal therapy (PTT) are often limited by mismatched pharmacokinetics and poor tumor localization of individual agents. In this study, we addressed these challenges by synthesizing carrier-free, aqueous nanoparticles (NPs) via the stoichiometric ion-pairing of Doxorubicin (DOX) and the near-infrared dye. Utilizing a controlled reprecipitation method, we successfully tuned the NP hydrodynamic diameter to investigate the relationship between nano-architecture and therapeutic performance. UV-Vis and fluorescence spectroscopy revealed size-dependent molecular packing, significantly influencing the non-radiative decay pathways. Systematic evaluation of the photophysical properties demonstrated that NPs exhibited a peak light-to-heat conversion efficiency, representing improvement over the free dye. This enhancement is attributed to the optimized fluorescence quantum yield of the nano-assembly, which facilitates superior photothermal performance under 808 nm laser irradiation. These results identify a critical size-performance threshold for [DOX][NIR] nanomedicines, providing a scalable and highly efficient platform for synergistic chemo-photothermal (chemo-PTT) cancer eradication.
Fatima Abbas, Fatima Abbas. Optimization of Dual Combination [DOX][NIR] Nanomedicine: Effect of Size Tuning on Photophysical Behavior and Photothermal Efficiency for Enhanced Anti-Tumor Activity [abstract]. In: Proceedings of AACR Drug Discovery and Development (AACR D3) Conference; 2026 Jul 21-24; Boston, MA. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(14_Suppl):Abstract nr A052.
Fatima Abbas· Clinical Cancer Research· 0 citations
Triple-negative breast cancer (TNBC) presents formidable treatment barriers due to dysfunctional vasculature and an immunosuppressive microenvironment. To address these challenges, we engineered a bioinspired near-infrared (NIR)-responsive copper–polyphenol nanoplatform, SCP, to implement a NIR-triggered “bridge-and-attack” therapeutic strategy. This nanoassembly was constructed through the coordination of salvianolic acid B (SAB) with copper ions and further stabilized by a polydopamine (PDA) shell. Upon NIR irradiation, SAB and Cu2+ were co-released from SCP, enabling simultaneous vascular remodeling and tumor cell killing. The released SAB promoted vascular normalization, increasing pericyte coverage to 51.6% and alleviating tumor hypoxia, thereby facilitating intratumoral penetration and immune-cell infiltration. Meanwhile, released Cu2+, together with PDA-mediated photothermal activation, induced cuproptosis and immunogenic cell death (ICD). This combined remodeling of the tumor microenvironment enhanced CD8+ T cell infiltration and achieved a tumor inhibition rate of 88.5% in 4T1 tumor-bearing mice with favorable systemic biosafety. Overall, this interfacial nanomaterial design integrates vascular normalization, photothermal-enhanced cuproptosis, and immunotherapy, providing a promising materials-based strategy for TNBC treatment.
This work demonstrates a safe and effective strategy for combating MDR infections through the combined action of photothermal therapy and nanozyme catalysis, offering promising potential for clinical wound management.
Weiwei Zhang, Lixiang Fan, Xuanjun Zhang et al.· ACS Applied Materials and In...· 0 citations
Urothelial carcinoma is a common urinary malignancy with high recurrence, easy progression to muscle-invasive disease, and resistance to conventional therapies. To address the clinical challenges of poor drug retention, low bioavailability, severe toxicity, and the inability of monotherapy to inhibit tumor recurrence and metastasis, a smart responsive nanoplatform (PMP@ED/Ba) based on mesoporous polydopamine (MPDA) was designed and constructed. This platform uses a thermosensitive phase-change material as a gatekeeper to co-load erdafitinib (FGFR inhibitor) and baicalein (antioxidant). Systematic characterizations confirmed the successful fabrication of the nanocomposite with uniform spherical morphology. Under 808 nm NIR irradiation, PMP@ED/Ba exhibited good concentration- and power-dependent heating and photothermal stability, with a photothermal conversion efficiency of 26.3%. The PCM gatekeeper enabled NIR triggered on-demand drug release, preventing premature leakage. DPPH/ABTS assays demonstrated potent non-enzymatic antioxidant activity, efficiently depleting ROS. Hemocompatibility and cytotoxicity tests confirmed good biocompatibility. In vitro and in vivo studies showed that PMP@ED/Ba plus NIR irradiation significantly suppressed T24 tumor growth through synergistic photothermal-chemotherapy, inducing extensive apoptosis and necrosis without major organ toxicity. This smart platform provides an efficient, low-toxicity strategy for locoregional treatment of urothelial carcinoma.
Fayou Zhou, Jun Wang, Rui Xu et al.· Colloids and Surfaces B: Bio...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
